HK/China Healthcare Analyst (ex-Fosun Pharma)

Xinyao (Criss) Wang

Over 15 years' experience in both finance and healthcare, covering clinic operations, investment and equity research in both China and overseas.

Pre-IPO Shenzhen SDMC Technology (PHIP Updates) - Some Points Worth the Attention

Pre-IPO Biwin Storage Technology (A/H Listing) - The Cycle Is About to Peak; Time to Quit?

Pre-IPO SHEIN Global Holdings (PHIP Updates) - Some Points Worth the Attention

Pre-IPO Guangdong Rong Tai Pharmaceutical - Low Profitability Is a Pain Point

Pre-IPO Shanghai Synyi Medical Technology - The Value of Healthcare AI Remains to Be Verified

Pre-IPO IMPACT Therapeutics - Thoughts on the Pipeline, the Concerns and Valuation Outlook

Equity Capital Markets

Pharmeyes Cayman Holding / Equity Capital Markets

<ul>
<li>The financial data of Pharmeyes presents a contradictory situation where "stability" and "stagflation" coexist, as this "slow-growth industry" is hard to support the market's expectations for high growth of Pharmeyes.</li>
<li>Although its pioneering channel DDI solution has first-mover advantage, due to accelerating technological iteration, Pharmeyes needs to continuously prove its data platform can cope with the impact of emerging technologies.</li>
<li>Valuation would be lower than Medlive due to lower growth rate and profit margin. P/S of 3-4.5x could be a relatively conservative estimate, reflecting its growth concerns and risk profile</li>
</ul>


The financial data of Pharmeyes presents a contradictory situation where "stability" and "stagflation" coexist, as this "slow-growth industry" is hard to support the market's expectations for high growth of Pharmeyes.
Although its pioneering channel DDI solution has first-mover advantage, due to accelerating technological iteration, Pharmeyes needs to continuously prove its data platform can cope with the impact of emerging technologies.
Valuation would be lower than Medlive due to lower growth rate and profit margin. P/S of 3-4.5x could be a relatively conservative estimate, reflecting its growth concerns and risk profile


Pre-IPO Pharmeyes Cayman Holding - The Technical Barriers Are Not High